{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:39Z","timestamp":1764510399975,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Scientific Research"},{"name":"Health and Labor Science Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.clml.2011.06.011","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T04:44:40Z","timestamp":1318308280000},"page":"483-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interstitial Pneumonia After Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Harumi","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.06.011_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.011_bib2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.011_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","article-title":"Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"99","author":"Oki","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2011.06.011_bib4","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.011_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.011_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3816\/CLM.2009.n.087","volume":"9","author":"Kato","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2011.06.011_bib7","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.011_bib8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.06.011_bib9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy\u2014rare but there!","volume":"50","author":"Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.06.011_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: a systematic literature review","volume":"35","author":"Liote","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clml.2011.06.011_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease","volume":"82","author":"Wagner","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.06.011_bib12","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.06.011_bib13","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.06.011_bib14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.011_bib15","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.21492","article-title":"Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients","volume":"104","author":"Ruiz-Soto","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.06.011_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdq008","article-title":"Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events","volume":"21","author":"Kato","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.06.011_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00007890-198807000-00010","article-title":"Interstitial pneumonitis following autologous bone marrow transplantation","volume":"46","author":"Wingard","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.06.011_bib18","first-page":"329","article-title":"Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma","volume":"6","author":"Jochelson","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.06.011_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/ije\/24.1.183","article-title":"Prognostic models and the propensity score","volume":"24","author":"Drake","year":"1995","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clml.2011.06.011_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000104866","article-title":"Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature","volume":"76","author":"Heresi","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.clml.2011.06.011_bib21","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.06.011_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.06.011_bib23","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.06.011_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.06.011_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF02982008","article-title":"CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications","volume":"74","author":"Maeda","year":"2001","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.06.011_bib26","first-page":"1","article-title":"Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America","volume":"53","author":"Benson","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clml.2011.06.011_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2002.03419.x","article-title":"Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres","volume":"117","author":"Pagano","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.06.011_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment","volume":"2","author":"Bienvenu","year":"2001","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2011.06.011_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","article-title":"Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection","volume":"14","author":"Shelton","year":"2009","journal-title":"Nephrology (Carlton)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:08Z","timestamp":1761870128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S2152265011002151"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.06.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Pneumonia After Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}